Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity

Obesity Surgery

Volumn 22, Issue 4, 2012, Pages 565-571

  Farina, Maria Grazia ^a   Baratta, Roberto ^a   Nigro, Angela ^a   Vinciguerra, Federica ^a   Puglisi, Concetta ^a   Schembri, Roberto ^a   Virgilio, Clara ^b   Vigneri, Riccardo ^a   Frittitta, Lucia ^a,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b GARIBALDI HOSPITAL   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

BIB; Intragastric balloon; Lifestyle intervention; Obesity therapy; Sibutramine

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SIBUTRAMINE; TRIACYLGLYCEROL; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG WITHDRAWAL; FEMALE; HEARTBURN; HUMAN; HYPERTENSION; INSOMNIA; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; INTRAGASTRIC BALLOON INSERTION; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MINIMALLY INVASIVE PROCEDURE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; BALLOON; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ITALY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RISK REDUCTION; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; APPETITE DEPRESSANTS; COMBINED MODALITY THERAPY; CYCLOBUTANES; FEMALE; GASTRIC BALLOON; HUMANS; ITALY; MALE; MIDDLE AGED; OBESITY; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84861838122     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-011-0514-y     Document Type: Article

References (30)

1. Despres JP, Pascot A, Lemieux I. Risk factors associated with obesity: a metabolic perspective. Ann Endocrinol (Paris). 2000;61 Suppl 6:31-8. (Pubitemid 32056455)
2. Vigneri P, Frasca F, Sciacca L, et al. Obesity and cancer. Nutr Metab Cardiovasc Dis. 2006;16(1):1-7.
3. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763-78. (Pubitemid 44285582)
4. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000;160(7):898-904.
5. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2:51S-209S.
6. Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring). 2009;17 Suppl 3:S43-8.
7. Long SD, O'Brien K, MacDonald KG, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care. 1994;17(5):372-5. (Pubitemid 24145209)
8. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322(7288):716-20. (Pubitemid 32238779)
9. Wing RR. Use of very-low-calorie diets in the treatment of obese persons with non-insulin-dependent diabetes mellitus. J Am Diet Assoc. 1995;95(5):569-72.
10. Doldi SB, Micheletto G, Perrini MN, et al. Intragastric balloon: another option for treatment of obesity and morbid obesity. Hepatogastroenterology. 2004;51(55):294-7. (Pubitemid 38283118)
11. Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841-6.
12. Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71(6):927-33.
13. Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611-7.
14. Busetto L, Segato G, De Luca M, et al. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg. 2004;14(5):671-6. (Pubitemid 38716590)
15. Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16(9):1135-7. (Pubitemid 44433148)
16. Frutos MD, Morales MD, Lujan J, et al. Intragastric balloon reduces liver volume in super-obese patients, facilitating subsequent laparoscopic gastric bypass. Obes Surg. 2007;17(2):150-4. (Pubitemid 47091574)
17. Roman S, Napoleon B, Mion F, et al. Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14(4):539-44. (Pubitemid 38570298)
18. Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients 1 year after the intragastric balloon has been removed? Obes Surg. 2005;15(6):864-70. (Pubitemid 40904880)
19. Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161-4. (Pubitemid 41390215)
20. Genco A, CiprianoM, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496-500.
21. Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics intragastric balloon (BIB). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5-9.
22. Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084-8.
23. Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg. 2008;18(8):989-92.
24. Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26(1):40-4. (Pubitemid 350308348)
25. Ganesh R, Rao AD, Baladas HG, et al. The Bioenteric Intragastric Balloon (BIB) as a treatment for obesity: poor results in Asian patients. Singapore Med J. 2007;48(3):227-31. (Pubitemid 351229391)
26. Dastis NS, Francois E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41(7):575-80.
27. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905-17.
28. Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007;17(5):565-8. (Pubitemid 46945427)
29. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462-70. (Pubitemid 29418240)
30. Vetter ML, Faulconbridge LF, Webb VL, et al. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol. 2010;6(10):578-88.